Latest available resultsQuarter ended June 30, 202610-Q · July 23, 2026
Filed with the SECWEST PHARMACEUTICAL SERVICES INC
WSTHealthcare
Next reportOctober 21, 2026pre-market · Analyst forecast 2.21 $/share
Revenue
$872.30M
▲ +13.8% vs prior year% YoY
Net income
$154.00M
▲ +16.8% vs prior year% YoY
EPS
2.15$
▲ +18.1% vs prior year% YoY
Net margin
17.7%
▲ +0.5 percentage points vs prior year pp YoY
Revenue▲ +13.8 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +16.8 %
EPS▲ +18.1 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $872.30M | |
| Gross profit | $329.20M | 37.7 % |
| Operating income | $179.10M | 20.5 % |
| Net income | $154.00M | 17.7 % |
| R&D | $19.70M | 2.3 % |
| EPS (diluted) | 2.15 $ | |
| Balance sheet | ||
| Assets | $4.08B | |
| Liabilities | $1.09B | |
| Equity | $2.99B | |
| Cash | $435.80M | |
| Capital | ||
| Shares outstanding | 70.38M | as of 2026-07-20 |
| Public float | — | |